About Allay Therapeutics
Allay Therapeutics is a company based in Menlo Park (United States) founded in 2017. Allay Therapeutics has raised $146.89 million across 6 funding rounds from investors including Evonik, HHS and Temasek. Allay Therapeutics offers products and services including Localized Pain Management Technology. Allay Therapeutics operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
- Headquarter Menlo Park, United States
- SectorsHealthcare
- Email••••••••
- Website allaytx.com
- Social LinkedIn X
- Legal Name Allay Therapeutics, Inc.
- Total Equity Funding$146.89M (USD)
in 6 rounds
- InvestorsEvonik
& 10 more
Products & Services of Allay Therapeutics
Allay Therapeutics offers a comprehensive portfolio of products and services, including Localized Pain Management Technology.
Technology designed to provide weeks of targeted pain relief for patients.
Funding Insights of Allay Therapeutics
Allay Therapeutics has successfully raised a total of $146.89M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $146.89M
- Total Rounds 6
- First Round $251,113
(Sep 2020)
- Investors Count 11
All 6 funding rounds of Allay Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2025 | – | Debt – Venture | – | – | |
| Jan 2025 | $45M | Series D | – | – | – |
| Dec 2022 | – | Series D | – | – | |
| Sep 2021 | $86.89M | Series C | – | Arboretum Ventures | |
| Jul 2021 | $15M | Series B | – | – | – |
| Sep 2020 | $251,113 | Grant | – | – |
11 investors in total: 11 institutional.
Investors in Allay Therapeutics
Allay Therapeutics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Evonik, HHS and Temasek.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare venture capital investments are made by Arboretum Ventures. | – | arboretumvc.com | Ann Arbor, United States | |
Venture capital investments are offered to startups by NEA. | – | nea.com | Menlo Park, United States | |
An investment platform is provided for diverse sectors and geographies. | 1974 | temasek.com.sg | Singapore, Singapore | |
Growth-stage companies are invested in by this venture capital fund. | – | pavilioncapital.com | New York, United States | |
- | – | vertexventureshc.com | - | |
Early & late stage investments focused PE & VC firm | – | vertexgrowth.com | - | |
- | – | wttinvestment.tcc.mode | - | |
Early-stage medical companies are funded by this venture capital firm. | – | brandoncapital.vc | Melbourne, Australia | |
Evonik is recognized as a leader in specialty chemicals innovation. | 1847 | evonik.com | Essen, Germany | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Allay Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Allay Therapeutics
22 people are tracked at Allay Therapeutics (7 in leadership, 10 in board & advisors, 5 in team).
| Name | Role | Group |
|---|---|---|
David Hewitt | Chief Medical Officer | Leadership |
Adam D. Gridley | Chief Executive Officer | Leadership |
Heather Berns | Vp, Clinical Operations | Leadership |
Betsy Beasley | Vice President Of Business Operations | Leadership |
Rachel Yan | Director, Clinical Operations | Leadership |
James Su | Sr Director Corporate Development And Strategy | Leadership |
Lindsay Taylor | Program Director | Leadership |
Mike Carusi | Director | Board & advisors |
Tak Cheung | Director | Board & advisors |
Mark Deem | Director | Board & advisors |
Leighton Read | Director | Board & advisors |
Joachim Kohn | Advisor | Board & advisors |
Ron Burch | Advisor | Board & advisors |
Josh Makower | Director | Board & advisors |
David Dalury | Advisor | Board & advisors |
Arthur Tipton | Advisor | Board & advisors |
Paul McCreadie | Director | Board & advisors |
Negar Shiraz | In-House Clinical Research Associate | Team |
Koon Kiat Teu | Gm, Singapore | Team |
Audrey Kwan | Engineer | Team |
2 more people are available in the full profile.
Complete people profiles for Allay Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Allay Therapeutics
3 dated milestones of Allay Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Allay Therapeutics is founded.
- Funding First funding round of $251K.
- Funding Latest funding round, Debt – Venture,.
Competitors of Allay Therapeutics
Allay Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| caratherapeutics.com | 2004 | New York, United States | $51M | 79 | Developer of therapeutics for pain relief and inflammatory diseases | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. | |
| ethypharm.com | 1977 | Saint Cloud, France | $248.09M | – | Therapies for pain and addiction treatment are developed. | |
| zogenix.com | 2006 | Emeryville, United States | $149.06M | 159 | Drug delivery systems for CNS disorders and pain are developed. | |
| painreform.com | 2007 | Herzliya, Israel | $12M | – | Pain treatment products are developed through reformulation technologies. | |
| herontx.com | 1983 | Redwood, United States | $32.14M | 21 | Reformulated injectables for chemotherapy side effects and pain are developed. | |
| trevena.com | 2007 | Philadelphia, United States | $203M | 35 | GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | |
| satsumarx.com | 2016 | San Francisco, United States | $74.13M | 24 | Therapeutics for migraine treatment are developed using nasal delivery. | |
| concentricanalgesics.com | 2014 | San Francisco, United States | $85.46M | – | Developer of platform for developing pro-drugs |
Detailed competitors of Allay Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Allay Therapeutics
The website of Allay Therapeutics (allaytx.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▼ 24.8% vs previous month
Latest news on Allay Therapeutics
Complete news archive for Allay Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Allay Therapeutics
10 companies that operate in the same segment as Allay Therapeutics (Orthopedics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Prosthetic and orthotic devices are developed for individuals with disabilities. | 1919 | Duderstadt, Lower Saxony, Germany | USD 17 M | USD 1.97 B | – | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of drugs for treating rare and autoimmune diseases | 2008 | Dublin, Ireland | USD 61.78 M | USD 617.41 M | – | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Robotic arms are provided for mobility and rehabilitation support. | 2004 | Boston, Massachusetts, United States | USD 17.21 M | USD 40.93 M | 185 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608 M | – | – | |
Exoskeletons for medical rehabilitation and industrial productivity are provided. | 2005 | United States | USD 24.37 M | USD 71.6 M | 61 | |
Stabilization devices for healthcare are manufactured by the company. | 2005 | New York, New York, United States | USD 142.15 M | – | 43 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Allay Therapeutics
Allay Therapeutics was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Allay Therapeutics is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Allay Therapeutics is a funded company, having raised a total of $146.89M across 6 funding rounds to date. The company's 1st funding round was a Grant of $251.11K, raised on Sep 2020.
Allay Therapeutics was founded in 2017 in Menlo Park, United States, within the biotechnology sector. Drugs for post-surgical pain management are developed through a proprietary platform that integrates non-opioid analgesics with biopolymers, resulting in dissolvable candidates for site-targeted relief. The lead candidate, ATX-101, is aimed at knee rehabilitation following surgery. Additional injectables, ATX-201 and ATX-301, are created for on-demand pain control.
Allay Therapeutics's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.
Allay Therapeutics offers Localized Pain Management Technology.
Allay Therapeutics has 11 investors. Key investors include Evonik, HHS, Temasek, Arboretum Ventures, and NEA.
Allay Therapeutics operates through Allay Therapeutics, Inc..